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Background: Transarterial chemo-embolisation (TACE) is recommended for patients with BCLC intermediate stage hepatocellular
carcinoma (stage B), particularly in patients with good underlying liver function and minimal symptoms. The hepatoma arterial
embolisation prognostic (HAP) score combines measures of liver function and tumour-related factors to offer a simple prognostic
scoring system. The Albumin-Bilirubin (ALBI) grade permits assessment of the impact of liver function on survival. We aimed to
investigate these two models and vascular invasion (VI).
Methods: In an international cohort of 3030 patients undergoing TACE, we examined the impact of liver function as assessed by
the ALBI score, the HAP score and VI on survival.
Results: Classification according to ALBI grade resulted in non-overlapping survival curves in the overall data set and all regional
cohorts. The HAP score was also validated. Tumour number, aetiology and VI were identified as additional independent
prognostic risk factors not currently included in the HAP score. Survival was particularly poor for patients with VI.
Conclusions: The ALBI grade categorised patients receiving TACE into three clear prognostic groups, thereby emphasising the
importance of underlying liver function in the outcome of TACE. The HAP score has been validated internationally and the serious
adverse impact of VI is clearly shown.
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International guidelines recommend Transarterial chemo-emboli-
sation (TACE) for patients with hepatocellular carcinoma (HCC)
at the BCLC intermediate stage (B) or for those patients in the
early stage that are not candidates for percutaneous ablation, liver
resection or transplantation (Bruix and Sherman, 2011). This
recommendation was based upon two randomised trials and a
subsequent systematic review (Llovet et al, 2002; Lo et al, 2002;
Llovet and Bruix, 2003). However, the benefits from TACE remain
controversial (Marelli et al, 2007; Curley et al, 2012; Meyer et al,
2013). A recent Cochrane review concluded that there was no firm
evidence to support or refute the benefit of TACE for patients with
unresectable HCC (Oliveri et al, 2011), although this conclusion
has, itself, been robustly challenged (Forner et al, 2012).
Nonetheless, there is little argument that the degree of
underlying liver (dys)function is an important factor determining
survival and hence in defining the patient groups most likely to
benefit from this form of treatment. International guidelines
suggest that TACE should be confined to those with Child-Pugh
(C-P) ‘A’ disease and that patients with vascular invasion (VI)
should receive sorafenib rather than TACE although VI was not
excluded in one of the original RCTs (Lo et al, 2002). However, it is
now well-established that TACE can be performed safely in the
presence of some degree of VI and, in current clinical practice, a
significant proportion of patients undergoing TACE do, in fact,
have VI. We have previously developed and validated a simple
model, the hepatoma arterial embolisation prognostic (HAP) score
(Kadalayil et al, 2013), based on a cohort of UK patients, that
permits assessment of prognosis after TACE. The model was built
on the clinical parameters of bilirubin, albumin, tumour size and
Albumin-Bilirubin (AFP), the former two presumably reflecting
the impact of liver function and the latter two, the impact of
tumour-related factors, on survival.
We have now assembled a comprehensive global data set that
includes patient level data from43000 patients undergoing TACE
and undertaken a rigorous statistical analysis of the factors
influencing survival. We placed particular emphasis on underlying
liver function and the presence or absence of VI and, in the process
thereof, we sought to validate the HAP score. Liver function was
assessed by applying the recently developed ALBI score (Johnson
et al, 2014), a simple objective and extensively validated (Chan
et al, 2015; Hiraoka et al, 2015; Chan et al, 2016), approach.
PATIENTS AND METHODS
The cohorts comprised patients undergoing TACE in four different
regions namely Europe, Japan, China (Hong Kong) and Egypt
(Table 1). The European cohort comprised 413 patients from the
UK (Birmingham, Liverpool and London), 731 from Germany
(Hannover and Freiburg) and 88 patients from Pamplona, Spain.
Some of the data from the UK (London) came from those on
which the HAP score was originally derived. These patients were
excluded for the HAP score validation. The Japanese cohort
(n¼ 655) were recruited from five institutions in the Western part
of Japan, as previously reported by Toyoda et al (2006). The
Chinese patients (n¼ 145) were from those attending the Joint
Hepatoma Clinic at the Prince of Wales Hospital, Hong Kong and
the Egyptian cohort (n¼ 998) were from those referred to the
Oncology department of the National Liver Institute in Shebeen
ElKom, Egypt. Detailed demographic data is given in Table 1. Data
recorded in each cohort include age, gender, albumin (g l 1),
bilirubin (mmol l 1), tumour number (solitary or multiple),
tumour size (cm), VI, AFP (ngml 1), C-P grade and aetiology
(HCV, HBV or ‘other’). ‘Other’ comprised mainly patients with
alcoholic liver disease. Laboratory data were recorded within the 6
week period before the first TACE procedure which was, in turn,
undertaken within 6 weeks of diagnosis. Vascular invasion
(including portal vein, hepatic vein and inferior vena cava
involvement) was assessed in the portal phase of computed
Table 1. Demographics
Variables Europe (n¼1232) Japan (n¼655) Egypt (n¼998) Hong Kong (n¼145) All (n¼3030)
% Male 83.12, n¼ 1232 74.66, n¼ 655 83.27, n¼998 85.52, n¼ 145 81.45, n¼ 2769
Age (median, IQR) 66.48 (59.00–73.18),
n¼ 1230
65.00 (58.00–73.00),
n¼655
57.00 (51.00–62.00),
n¼ 998
65.00 (56.00–71.00),
n¼ 145
62.77 (55.00–70.07),
n¼ 3028
Albumin, g l 1 (median, IQR) 37.00 (33.00–41.00),
n¼ 1214
32.00 (28.00–36.00),
n¼653
33.00 (29.00–37.00),
n¼ 998
35.00 (32.00–39.00),
n¼ 145
35.00 (30.00–39.00),
n¼ 3010
Bilirubin, mmol l 1 (median, IQR) 16.00 (10.94–26.00),
n¼ 1213
15.39 (11.97–23.94),
n¼653
22.23 (13.68–32.49),
n¼ 998
14.00 (9.00–22.00), n¼ 145 17.10 (11.97–27.36),
n¼ 3009
Tumour size, cm (median, IQR) 5.00 (3.40–7.60), n¼ 1180 3.50 (2.20–5.40), n¼ 594 6.00 (4.00–8.00), n¼ 998 6.00 (3.80–10.00), n¼ 141 5.00 (3.40–7.60), n¼ 2913
% Multifocal 66.24, n¼ 1161 69.27, n¼ 654 75.75, n¼998 58.33, n¼ 144 69.73, n¼ 2957
AFP, ngml 1 (median, IQR) 46.00 (6.70–534.50),
n¼ 1045
45.45 (12.40–510.00),
n¼614
129.00 (17.00–600.00),
n¼ 998
92.00 (10.00–1365.00),
n¼ 145
70.45 (11.00–584.00),
n¼ 2802
INR (median, IQR) 1.10 (1.01–1.20), n¼ 851 NA 1.40 (1.20–1.70), n¼ 998 1.14 (1.07–1.22), n¼ 145 1.20 (1.10–1.40), n¼ 1994
ALBI score (median, IQR) 2.34 ( 2.72 to  1.91),
n¼ 1203
 1.97 ( 2.36 to  1.55),
n¼653
 1.91 ( 2.34 to  1.55),
n¼ 998
 2.29 (2.59 to  1.90),
n¼ 145
 2.10 ( 2.53 to 1.67),
n¼ 2999
% ALBI grade (1 : 2 : 3) 32.09 : 60.93 : 6.98, n¼ 1203 13.02 : 70.75 : 16.23,
n¼653
15.63 : 69.14 : 15.23,
n¼ 998
24.83 : 67.59 : 7.59, n¼ 145 22.11 : 66.12 : 11.77,
n¼ 2999
% Child-Pugh (A : B :C) 73.94 : 24.62 : 1.45, n¼ 1174 52.06 : 41.22 : 6.72, n¼ 655 47.60 : 46.89 : 5.51,
n¼ 998
77.24 : 21.38 : 1.38, n¼ 145 60.43 : 35.60 : 3.97,
n¼ 2972
% HAP class (A : B:C:D) 18.72 : 34.42 : 31.95 : 14.91,
n¼ 892 (Liverpool,
Birmingham, Germany and
Spain only)
13.49 : 32.40 : 38.53 : 15.59,
n¼571
9.02 : 22.55 : 41.08 : 27.35,
n¼ 998
12.06 : 37.59 : 29.79 : 20.57,
n¼ 141
13.49 : 29.59 : 36.78 : 20.14,
n¼ 2602
% Vascular invasion 10.61, n¼ 1225 30.28, n¼ 654 10.32, n¼998 11.03, n¼ 145 14.79, n¼ 3022
% HCV :HBV : other 24.29 : 12.19 : 63.52,
n¼ 1165
56.66 : 18.42 : 24.92,
n¼646
98.39 : 1.10 : 0.50, n¼996 8.33 : 79.86 : 11.81, n¼ 144 55.61 : 13.11 : 31.28,
n¼ 2951
Overall survival (months, 95% CI) 16.6 (15.4–18.0), n¼ 1226 22.3 (20–24.5), n¼ 655 18.0 (17.0–19.0), n¼ 998 19.9 (14.2–25.6), n¼ 143 18.6 (17.9–19.5), n¼ 3022
Abbreviations: AFP¼ alphafetoprotein; ALBI¼Albumin-Bilirubin; CI¼ confidence interval.
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tomography and, supplemented where appropriate, by arterial
portography. Assessments were made within the 6 week period
before treatment. In the Japanese cohort detailed information
concerning the extent of portal vein invasion, ranging from VP0 to
VP4 was recorded. VP0 indicated no tumour thrombus in the
portal vein; VP1, tumour thrombus distal to, but not involving,
the second-order branches; VP2, tumour thrombus in the
second-order branches; VP3, tumour thrombus in the first-order
branches; and VP4, tumour thrombus in the main trunk (Katagiri
and Yamamoto, 2014; Kudo et al, 2015). For the purposes of the
present analysis, VP2 and VP3 were combined.
The centres involved had extensive experience in the manage-
ment of HCC and the use of TACE. We included all patients that
were classified by the local investigator as undergoing TACE as
their primary treatment, excluding only those where TACE was
used as a bridge to transplantation or other potentially curative
treatment options. Neither the response, nor any specific aspects of
the procedure such as type of cytotoxic drug or embolic agent used
or frequency of repeat TACE, or other treatment after the primary
treatment, were recorded for the purpose of this study. All data
were analysed in the UK (University of Liverpool) and used exactly
as presented by the contributing investigator. Liver function was
assessed by the C-P grade (as graded by the local investigator) and
the ALBI score, the latter being graded according to the published
cutoff points. Grades 1, 2 and 3 refer to good, intermediate and
poor liver function, respectively.
Statistical methods. All statistical analyses were undertaken using
Stata/SE 14.1 (StataCorp LLC, Lakeway Drive, TX, USA). The HAP
score (Kadalayil et al, 2013) and ALBI grade (Johnson et al, 2014)
were calculated as previously described. Survival (in months) was
calculated from date of TACE treatment until date of death or
date of last follow-up. Survival according to HAP score or ALBI
grade was plotted using the Kaplan–Meier method. The different
classification systems were compared using the Harrell’s C (a
measure of predictive power; Harrell et al, 1982; Harrell et al, 1996;
Newson, 2010) and Akaike information criterion (AIC; a measure
of model fit; Akaike, 1998). Higher values of the former and lower
values of the latter indicates a better prognostic utility of the model.
Log-rank tests were used to compare between the survival curves
within each staging group. Alphafetoprotein (AFP) and bilirubin
were log-transformed due to extreme skewness. Variables that
influence survival were identified using univariable Cox propor-
tional hazards model. Using forward selection of variables at the
P¼ 0.05 level (and likelihood ratio test at each step), a multi-
variable Cox proportional hazards model was built to explain
survival in TACE patients. For the Cox regression models, all the
cohorts were merged and ‘region’ was used as a frailty term. The
proportional hazards assumption was tested on the basis of scaled
Schoenfeld residuals after fitting the Cox regression model. For all
tests, statistical significance level was set at 5%.
RESULTS
The results from the univariable Cox regression analysis (Table 2)
showed that albumin, bilirubin, tumour number, tumour size, VI
and aetiology were prognostic in patients undergoing TACE (all
Pp0.0001). The multivariable Cox regression model (Table 3)
showed that the key variables influencing survival were related to
tumour characteristics (tumour size, tumour number, AFP and VI;
Po0.0001), liver function (albumin and bilirubin) (Po0.0001),
aetiology (P¼ 0.0082) and age (P¼ 0.0012; Table 3). Effect of age
on survival was more notable in those over 70 years of age
compared with the other age groups (Table 3; Supplementary
Table 1). Most patients had CP grade ‘A’ liver function; the
remainder had CP grade B with only a small percentage (4%)
having CP grade C (Table 1). Assessing liver function by the
two variables of bilirubin and albumin as defined in the ALBI
score revealed a clear discrimination in survival between each
ALBI grade in all separate regions (Figures 1A–D) and overall
(Figure 2A). The model also revealed clear separation within C-P
‘A’ patients (Figure 2B; Supplementary Figures 1a–d). Assessing
liver function with the C-P score also showed separation by grade
in each individual region (Supplementary Figures 2a–d). There
was no clear difference between C-P B and C-P C particularly
amongst the European, Japanese and Hong Kong cohorts but, asTable 2. Univariable Cox regression
Variable
Hazard ratio
(95% CI)
P-value LR test of
theta¼0
Age groups
Under 51 1
51–60 0.967 (0.822–1.138) 0.688
61–70 0.914 (0.779–1.072) 0.269
Over 70 0.950 (0.805–1.122) 0.546 0.003
Gender
Female 1
Male 1.099 (0.980–1.234) 0.108 0.005
Albumin (g l 1) 0.958 (0.951–0.966) o0.0001 o0.0001
Log 10 bilirubin 1.894 (1.608–2.231) o0.0001 0.007
Tumour number
Solitary 1
Multiple 1.279 (1.158–1.412) o0.0001 0.005
Tumour size (cm) 1.072 (1.059–1.086) o0.0001 0.084
Vascular invasion
No 1
Yes 2.282 (2.024–2.573) o0.0001 o0.0001
Log 10 AFP 1.263 (1.215–1.312) o0.0001 o0.0001
Aetiology
HCV 1
HBV 1.211 (1.055–1.391) 0.007
Other 1.276 (1.138–1.432) o0.0001 0.077
Abbreviations: AFP¼ alphafetoprotein; CI¼ confidence interval; HCV¼ hepatitis C virus;
HBV¼ hepatitis B virus.
Table 3. Multivariable Cox regression
Variable Hazard ratio (95% CI) P-value
Vascular invasion
No 1
Yes 1.751 (1.515–2.025) o0.0001
Albumin (g l1) 0.959 (0.950–0.968) o0.0001
Log10 AFP 1.209 (1.158–1.261) o0.0001
Tumour size (cm) 1.054 (1.038–1.070) o0.0001
Log10 bilirubin 1.697 (1.394–2.066) o0.0001
Tumour number
Solitary 1
Multiple 1.284 (1.151–1.432) o0.0001
Age groups
Under 51 1
51–60 0.946 (0.793–1.130) 0.541
61–70 0.943 (0.791–1.123) 0.508
Over 70 1.209 (1.000–1.463) 0.05
Aetiology
HCV 1
HBV 1.233 (1.050–1.449) 0.011
Other 1.231 (1.076–1.408) 0.002
Abbreviations: AFP=alphafetoprotein; CI¼ confidence interval; HCV¼ hepatitis C virus;
HBV¼ hepatitis B virus. Theta¼ 0.0185, LR test of theta¼ 0, chibar2(01)¼ 17.83, Po0.0001.
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expected, the numbers in the C-P C group were low. Results after
merging the data sets from all four regions showed clear separation
between the three C-P grades (Figure 2C). Both by visual
inspection and formal statistical analysis (via Harrell’s C statistic),
the ALBI score is at least as effective as C-P in discriminating
between prognostic groups. Harrell’s C statistic was 0.5661 and
0.5586 for ALBI and C-P, respectively. The corresponding AIC
values were 26963.33 and 26548.21, respectively.
The HAP score was originally developed using the UK data sets
only (London). Applying the HAP score to each of the other
cohorts – Europe (Liverpool, Birmingham, Spain and Germany),
Japan, Egypt and Hong Kong – produced four prognostic groups
in each region (Supplementary Figures 3a–d) and overall
(Figure 2D), thereby extending the generalisability of the score,
although it should be noted that there was considerable overlap
between HAP 2 and 3 in the Egyptian (Supplementary Figure 3c),
and to a lesser extent the Hong Kong cohorts (Supplementary
Figure 3d). Merging all the cohorts, however, generated four clear
prognotic groups (log-rank tests, Po0.0001 for all combinations;
Figure 2D).
Overall 15% of patients had VI and there was a very clear
difference in survival according to presence or absence thereof, in
all regions (Supplementary Figures 4a–d) and overall (Figure 2E).
Among those with VI survival was particularly poor, ranging from
2.7–10.7 months in the various regions and 8.2 months overall
(Supplementary Figures 4a–d; Figure 2E). In the Japanese cohort,
there was clear deterioration in overall survival with increasing
extent of the portal vein involvement (Figure 2F).
Median survival (and 95% CI) for each of the above sub-groups,
as well as the Harrell’s C and AIC scores are summarised in Table 4
and Supplementary Table 2. Log-rank test outcomes for each
combination of the survival curves in all the figures is summarised
in Supplementary Table 3.
DISCUSSION
Our multivariable analysis showed that the key variables influen-
cing survival were related to tumour characteristics (tumour size,
tumour number, AFP and VI), liver function (albumin and
bilirubin) and aetiology. These results were largely in agreement
with the literature (Savastano et al, 1999; Llado´ et al, 2000;
O’Suilleabhain et al, 2003; Grieco et al, 2005; Takayasu et al, 2006)
and our previous analysis (based largely on the current UK data
set). In the latter, we used bilirubin, albumin, tumour size and AFP
to develop a score (the HAP score) that gave accurate and
nationally validated prognostication (Kadalayil et al, 2013). The
present study lends international support to the HAP score, but as
noted above there is considerable overlap between HAP stages B
and C in the Chinese and Egyptian cohorts.
However, the data set on which the HAP score was originally
developed did not contain information on tumour number and the
number of patients with different aetiologies and VI was too small
for meaningful statistical analysis; these parameters did not,
therefore, enter the model. Thus, it became apparent in the
present, much larger and international data set, that VI, tumour
number, age and aetiology were also important, and these factors
could be added to the HAP score to increase its prognostic utility.
It would be possible to build a more rigorous model involving
these variables, but the inevitable increase in complexity would
detract from relative simplicity and ready clinical applicability
of the currently formulated HAP score. Our data sets were
accrued before the recent publication of other scoring systems
designed to facilitate identification of patients appropriate for
TACE and we have not therefore collected the variables that
would be required for comparison with HAP (Hucke et al, 2014;
Adhoute et al, 2015).
0.00
0.25
0.50
0.75
1.00
A B
C D
0 20 40 60
Survival in months
ALBI grade 1 ALBI grade 2
ALBI grade 3
ALBI grade 1 ALBI grade 2
ALBI grade 3
ALBI grade 1 ALBI grade 2
ALBI grade 3
ALBI grade 1 ALBI grade 2
ALBI grade 3
European patients undergoing TACE
0.00
0.25
0.50
0.75
1.00
0 20 40 60
Survival in months
Japanese patients undergoing TACE
0.00
0.25
0.50
0.75
1.00
0 10 20 30 40
Survival in months
Egyptian patients undergoing TACE
0.00
0.25
0.50
0.75
1.00
0 20 40 60
Survival in months
Hong Kong (China) patients undergoing TACE
Figure 1. Kaplan–Meier curves depicting survival according to ALBI grade. Patients are classified as undergoing TACE from (A) Europe, (B) Japan,
(C) Egypt and (D) Hong Kong, China.
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Our results also give particular insight into two of the key
prognostic variables that are integral to the model namely liver
function and VI. Thus albumin and bilirubin are clear measures of
liver (dys) function and form the basis of our ALBI score. In all
regions there is clear discrimination in survival according to ALBI
and this was also maintained within patients classified as C-P ‘A’.
Despite this clear discrimination within regional groups, the
percentage falling into each ALBI group and the survival within
each group was different. This presumably reflects the different
availability of, and indication for, various therapeutic options and
treatment algorithms in the different regions and the different
aetiologies. For example, Sorafenib was not available in Egypt and
liver transplantation was not available in the Japanese or Hong
Kong cohorts. It should be noted here that the ALBI score is not an
HCC staging system since it only measures liver function, taking
no account of tumour-related factors. To this extent it is not
directly comparable to the HAP score which was derived to assess
survival after arterial therapies by combining both liver function
and tumour-related factors.
Our current analysis suggests that the ALBI score is at least as
discriminatory, in prognostic terms, as the CPS in the TACE setting
and in a recent study on a similar population, but including those
undergoing radio-embolisation, Hickey et al (2016) concluded that the
ALBI score ‘outperformed’ the CPS in discriminating survival. Even
without any claim to superiority over the CPS, the ALBI score/grade
has several advantages. Specifically, it does not require three of the five
parameters involved in the CPS (including the two that are most
subjective, ascites and encephalopathy), thereby making the classifica-
tion more reliable between observers. A less obvious advantage is that it
was built on an extensive evidence base, specifically for assessment of
liver function in HCC and made no prior assumptions as to the
presence or absence of cirrhosis. By contrast, the CPS is advocated for
the assessment of liver function in patients with cirrhosis and, at least
by convention, it should only be applied to such patients. This
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Figure 2. Kaplan–Meier curves depicting survival in all the patients undergoing TACE. Patients are classified according to (A) ALBI grade,
(B) ALBI grade within C-P grade A, (C) C-P grade, (D) HAP class, (E) the presence or absence of macrovascular invasion and (F) the extent of
vascular invasion (Japan).
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convention is generally not applied to patients with HCC being used
widely, even with the knowledge that many patients with HBV-related
HCC will not have cirrhosis. In our recent study, where we examined
the extent of fibroses in resected HCC specimens and even among the
Japanese patients, most of whom had HCV-related HCC, only 52%
had cirrhosis (Toyoda et al, 2016a). It should not be assumed
therefore that, because all patients with HCC were assigned a CPS
by their local investigator, that all had cirrhosis.
The prevalence of VI (15%) is in line with reports in the literature
(Pirisi et al, 1998; Minagawa and Makuuchi, 2006; Yoshidome
et al, 2011; Quirk et al, 2015; 10–40%) and confirms that despite
guidelines, suggesting that patients with VI should receive sorafenib,
a significant proportion of those undergoing TACE did in fact have
VI. The prognostic importance of VI is also seen in patients treated
with curative intent (Toyoda et al, 2016b). Although the AASLD/
EASL guidelines (Llovet et al, 2008a) suggest the treatment with
sorafenib rather than TACE for those with any degree of VI there is
no explicit statement that suggests that VI is a contraindication to
TACE and the data presented here suggest the extent of portal vein
invasion is of major prognostic importance. Quirk et al (2015), have
noted that overall survival after TACE in patients with VI ranges
from 7.4 to 10.2 months in the literature (and in the series reported
here), figures that are only marginally better than those obtained
with systemic sorafenib (Llovet et al, 2008b).
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